Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR6 | P51684 | 1/20 | 0.48 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TGM2 | P21980 | 1/20 | 0.43 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.43 |
| ▸ | TPSD1 | Q9BZJ3 | 2/20 | 0.43 |
| ▸ | TPSG1 | Q9NRR2 | 2/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.43 |
| ▸ | CPB1 | P15086 | 1/20 | 0.42 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20467679 | 0.97 | CCR6 (0.51) | CCR6PAX8HTTMAPTCA14 | |
| SCHEMBL10647524 | 0.95 | CCR6 (0.51) | CCR6PAX8HTTMAPTCA14 | |
| SCHEMBL13426204 | 0.93 | MAPT (0.51) | CCR6PAX8HTTMAPTCA14 | |
| SCHEMBL20450598 | 0.91 | HTT (0.46) | CCR6PAX8HTTMAPTCA14 | |
| SCHEMBL4704081 | 0.90 | CCR6 (0.60) | CCR6PAX8HTTMAPTLMNA | |
| SCHEMBL9772169 | 0.89 | MAPT (0.55) | CCR6PAX8HTTMAPTCA14 | |
| SCHEMBL3770984 | 0.88 | HTT (0.59) | CCR6PAX8HTTMAPTLMNA | |
| SCHEMBL24198657 | 0.88 | MAPT (0.52) | HTTMAPTLMNASMN1; SMN2TGM2 | |
| SCHEMBL9766146 | 0.88 | CCR6 (0.52) | CCR6PAX8HTTMAPTCA14 | |
| SCHEMBL4793682 | 0.88 | MAPT (0.52) | CCR6PAX8HTTMAPTHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3580232-B1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2023-09-20 | — | — | EP | disclosed |
| US-20220211812-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2022-07-07 | — | — | US | disclosed |
| US-11364281-B2 | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and pharmaceutical compositions thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-06-21 | — | — | US | disclosed |
| US-11224634-B2 | — | — | 2022-01-18 | — | — | US | disclosed |
| US-11185570-B2 | Method of treating cardiovascular disease and heart failure with modified relaxin polypeptides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-11-30 | — | — | US | disclosed |
| US-20210196791-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2021-07-01 | — | — | US | disclosed |
| US-20190256570-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-08-22 | — | — | US | disclosed |
| US-10266578-B2 | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-23 | — | — | US | disclosed |
| WO-2018148419-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-08-16 | — | — | WO | disclosed |
| US-20180222960-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2018-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210196791-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | RXFP2, RXFP1, RXFP4 | CCR6 1003/4885PAX8 1219/4885HTT 3328/4885 |
| US-20190256570-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | RXFP2, RXFP1, RXFP4 | CCR6 1003/4885PAX8 1219/4885HTT 3328/4885 |
| US-20180222960-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | RXFP2, RXFP1, RXFP4 | CCR6 1003/4885PAX8 1219/4885HTT 3328/4885 |
| US-11364281-B2 | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and pharmaceutical compositions thereof | RXFP2, RXFP1, RXFP4 | CCR6 879/4885PAX8 1361/4885HTT 3701/4885 |
| US-20220211812-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | RXFP2, RXFP1, RXFP4 | CCR6 1003/4885PAX8 1219/4885HTT 3328/4885 |
| US-11224634-B2 | — | RXFP2, RXFP1, RXFP4 | CCR6 1490/4885PAX8 1492/4885HTT 3221/4885 |
| US-10266578-B2 | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof | RXFP2, RXFP1, RXFP4 | CCR6 1003/4885PAX8 1219/4885HTT 3328/4885 |
| US-11185570-B2 | Method of treating cardiovascular disease and heart failure with modified relaxin polypeptides | RXFP2, RXFP1, RXFP4 | CCR6 827/4885PAX8 1582/4885HTT 2789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.